Deepverge modelled, for example, the cruise line industry as a potential international customer seeking to offer its travellers a safe holiday environment, while potentially also providing a solution for insurance companies that are required to underwrite such excursions. Industry analysis suggests the global cruise line industry provides services to c.32m passengers annually with 1.1m full time employees. Based on onboard utilisation of both Microtox PD and Microtox BT and assuming one daily breath test for each individual (priced at £4 per test) plus five installed Microtox PD units installed on each ship for 24/7 monitoring, Deepverge calculates a prospective annual market opportunity equivalent to £2.6 billion. https://www.deepverge.com/wp-content/uploads/2021/01/Deepvergeplc_Research_Update_11January2021__FINAL_BG.01.pdf
Modern Water has been working for the past 12 months with its labs in York UK, its AI and photonics team in Europe, US and China and research institutions/universities around the world. Its technology expands on a microfluidic/photonics/AI instrument that the company started developing in 2015 in the University of Cambridge to detect E. coli in water (launched in December 2019). The company has successfully constructed nanochips coated with Affimers or Aptamers that bind the spike protein of SARS-CoV-2. Affimers and Aptamers are small proteins or oligonucleotides that bind proteins with a similar affinity and specificity to antibodies, without the steric hindrance of a large molecule. Microtox PD is detecting that binding in real time.